Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans
Table 2
Matching weight-adjusted incidence rates and hazard ratios for the primary and secondary outcomes among inpatient Veterans with treated hypertension who were current users of an ARB/ACEI- vs. non-ARB/ACEI-based antihypertensive regimen and ARB user vs. ACEI user, separately.